Expected DOAC steady-state peak and trough plasma concentrations
| Direct oral anticoagulant . | Dose . | Expected peak plasma concentration (ng/mL)b . | Expected trough plasma concentration (ng/mL) . |
|---|---|---|---|
| Apixaban | 5 mg twice daily | 132 (59-302) VTE 171 (91-321) AFib | 103 (41-230) |
| Rivaroxaban | 10 mg once daily | 125 (91-196) | 26 (6-87) |
| 15 mg once daily | 229 (178-313) | ||
| 20 mg once daily | 270 (189-419) VTE 249 (184-343) AFib | ||
| Edoxaban | 30 mg once daily | 164 (99-225) VTE 169 (10-400) Afib | 22 (10-40)c |
| 60 mg once daily | 234 (149-317) VTE 300 (60-569) Afib | ||
| Dabigatran | 110 mg twice daily | 126 (52-275) | 90 (31-225) |
| 150 mg twice daily | 175 (74-383) |
| Direct oral anticoagulant . | Dose . | Expected peak plasma concentration (ng/mL)b . | Expected trough plasma concentration (ng/mL) . |
|---|---|---|---|
| Apixaban | 5 mg twice daily | 132 (59-302) VTE 171 (91-321) AFib | 103 (41-230) |
| Rivaroxaban | 10 mg once daily | 125 (91-196) | 26 (6-87) |
| 15 mg once daily | 229 (178-313) | ||
| 20 mg once daily | 270 (189-419) VTE 249 (184-343) AFib | ||
| Edoxaban | 30 mg once daily | 164 (99-225) VTE 169 (10-400) Afib | 22 (10-40)c |
| 60 mg once daily | 234 (149-317) VTE 300 (60-569) Afib | ||
| Dabigatran | 110 mg twice daily | 126 (52-275) | 90 (31-225) |
| 150 mg twice daily | 175 (74-383) |
Adapted from Rottenstreich et al, J Thromb Thrombolysis. 2018;45(4):543-549; Gosselin et al, Thromb Haemost. 2018;118(3):437-450; Ezekowitz et al, Am J Cardiol. 2007;100(9):1419-1426; Mueck et al, Clin Phrarmacokinet. 2014;53(1):1-16; Weitz et al, Thromb Haemost. 2010;104(3):633-641.
Peak plasma concentrations are expressed as median (5th-95th percentile range) with the exception of dabigatran 110 mg twice daily, which is expressed as median (10th-90th percentile range).
Interquartile range.
AFib, atrial fibrillation.